Castle Biosciences (CSTL) Other Non-Current Liabilities (2019 - 2026)

Castle Biosciences has reported Other Non-Current Liabilities for 9 years, with the latest figure at $1.5 million in Q1 2026.

• Quarterly Other Non-Current Liabilities changed N/A year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (changed N/A YoY) and the FY2025 annual result came in at $1.5 million, changed N/A from the prior year.
• Other Non-Current Liabilities steadied at $1.5 million in Q1 2026 per CSTL's latest filing, from $1.5 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $2.5 million in Q2 2025 and troughed at $16000.0 in Q1 2024.
• A 5-year average of $1.0 million and a median of $800000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
• The widest YoY moves for Other Non-Current Liabilities: up 59833.33% in 2022, down 99.51% in 2022.
• Over 5 years, Other Non-Current Liabilities stood at $90000.0 in 2022, then slumped by 60.0% to $36000.0 in 2023, then slumped by 55.56% to $16000.0 in 2024, then soared by 9275.0% to $1.5 million in 2025, then changed by 0.0% to $1.5 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $1.5 million, $1.5 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.